GoodRx Appoints Raj Beri as Chief Operating Officer, Mark Hull as Chief Product Officer and Vina Leite as Chief People Officer
The company bolsters its leadership team with experienced mission-driven executives
SANTA MONICA, Calif. – May 9, 2022 -- GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it has made key leadership appointments to support the company’s scaling business and accelerate innovation to bring more affordable and convenient healthcare to consumers across the country.
Raj Beri will join GoodRx as the company’s first ever Chief Operating Officer (COO) from Uber, where he served as Vice President of Grocery and New Verticals, overseeing the company’s non-restaurant and last mile delivery businesses across global markets. With more than 20 years in the business operations space, Raj will lead continued growth and expansion at GoodRx, while helping increase value across the prescriptions business.
“GoodRx has seen tremendous growth over the past few years and I am eager to help lead the company through the next phase of its evolution as part of this innovative leadership team,” said Beri. “I’m passionate about working on audacious problems across sectors that are ripe for disruption, and GoodRx is at the center of that disruption in the healthcare industry.”
In addition, Mark Hull has been named the first ever Chief Product Officer to help the company build industry-leading solutions for consumers, providers and pharmacists. Previously a senior product executive at Meta and LinkedIn, Mark will draw on his more than 25 years of experience in the product management industry to make GoodRx more accessible, convenient and useful for consumers, while helping scale opportunities with partners.
Vina Leite has joined GoodRx as the company’s first Chief People Officer. With expertise in the global human resources and talent management space, Vina brings more than two decades of experience in transforming high-growth and Fortune 500 organizations. Vina will support growth at GoodRx by helping to develop scalable people operations functions while hiring and developing top talent in an environment that is empowered by diversity, equity and inclusion.
The company also welcomes Scott Paul as Senior Vice President of Healthcare & Consumer Innovation. Scott will leverage his substantial healthcare experience and knowledge to work with senior leadership on all areas of healthcare innovation across the ecosystem of consumers, retailers, PBMs, providers and drug manufacturers. Scott previously founded Apex Affinity, where he created and ran many of the largest pharmacy discount programs in the market, and most recently served as Executive Vice President at MedImpact, where he focused primarily on consumer savings and digital health.
“As GoodRx continues on our rapid growth trajectory, we’re thrilled to welcome these mission-driven additions to our leadership team,” said Doug Hirsch, co-CEO and co-founder of GoodRx. “Raj, Mark, Vina and Scott are innovative, forward-thinking executives who believe in GoodRx’s vision and core values. Their deep experience and expertise across consumer-driven, B2B and healthcare industries will be invaluable to GoodRx as we continue to help millions of consumers access affordable and convenient healthcare.”
Andrew Slutsky will transition to a new role at the company, driving new initiatives as Senior Vice President of Strategy & Marketing Innovation.
About GoodRx
GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $35 billion and are one of the most downloaded medical apps over the past decade.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements, including without limitation
statements regarding our future operations, growth and financial results and the benefits of new hires.
These statements are neither promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual results, performance or
achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including, but not limited to, the satisfaction of
the closing conditions of the vitaCare acquisition, risks associated with acquired businesses, including
risks related to our limited operating history and early stage of growth; our ability to achieve broad
market education and change consumer purchasing habits; our ability to continue to attract, acquire
and retain consumers in a cost-effective manner; our reliance on our prescription transactions offering
and ability to expand our offerings; changes in medication pricing and pricing structures; our inability to
control the categories and types of prescriptions for which we can offer savings or discounted prices;
our reliance on a limited number of industry participants; the competitive nature of industry; our ability
to attract, develop, motivate and retain well-qualified employees; and the other important factors
discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended
December 31, 2021, and our other filings with the SEC. These factors could cause actual results to differ
materially from those indicated by the forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of the date of this press release.
While we may elect to update such forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views to change.
Press Contact
GoodRx
Lauren Casparis
Investor Contact
GoodRx
Whitney Notaro
# # #